Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead to Present at Upcoming Scientific Conferences

Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that academic collaborators and scientists from the company will present data on the Dynamic PolyConjugate™ (DPC) siRNA delivery system, the ARC-520 hepatitis B drug candidate, and the Homing Peptide™ platform at upcoming scientific conferences.

Arrowhead to Present at Upcoming Scientific Conferences

Pasadena, CA | Posted on February 2nd, 2013

"The pace of innovation by our scientists in Madison over the last year has been impressive," said Dr. Christopher Anzalone, President and Chief Executive Officer. "We have made important progress, particularly with new subcutaneous and tumor-targeted DPCs and our ARC-520 HBV clinical program, which we are eager to discuss at conferences and through peer-reviewed publications."

Scheduled conference presentations in February are as follows:

The Sixteenth International Symposium on Recent Advances in Drug Delivery Systems - Salt Lake City, Utah, February 3-6, 2013

A poster titled, "Hepatocyte-Targeted Melittin-Like Peptide (MLP) as A New Endosomolytic Excipient for Liver Delivery of Therapeutic siRNAs: Biodistribution and Elimination," will be presented by Vladimir S. Trubetskoy, PhD, Senior Scientist;

A poster titled, "Novel Maleic Anhydride Based Polymer Masking Reagents for Targeted siRNA Delivery with Dynamic Polyconjugates," will be presented by Andrei Blohkin, PhD, Senior Scientist;

An oral presentation titled, "Ligand-directed Therapy and Molecular Imaging Based on in vivo Phage Display Technology," will be presented by Renata Pasqualini, PhD, Helen Buchanan & Stanley Seeger Professor of Medicine and Experimental Diagnostic Imaging, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX;

An oral presentation titled, "Ligand-directed Targeting and Imaging in Translational Medicine," will be presented by Wadih Arap, MD, PhD, Stringer Professor of Medicine and Experimental Diagnostic Imaging, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX;

AsiaTIDES: Oligonucleotide and Peptide Research, Technology and Product Development - Tokyo, Japan, February 26-28, 2013

An oral presentation titled, "Dynamic Polyconjugate (DPC) Technology for Targeted siRNA Delivery," will be presented by David Lewis, PhD, Vice President, Biology and Madison Site Head.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus infection. The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs.

For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Research
Vince Anzalone, CFA
626-304-3400

The Trout Group, LLC
Lauren Glaser
646-378-2972

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Scientists find a way of acquiring graphene-like films from salts to boost nanoelectronics: Physicists use supercomputers to find a way of making 'imitation graphene' from salt July 30th, 2016

Vortex laser offers hope for Moore's Law: The optics advancement may solve an approaching data bottleneck by helping to boost computing power and information transfer rates tenfold July 30th, 2016

New method for making green LEDs enhances their efficiency and brightness July 30th, 2016

A new type of quantum bits July 29th, 2016

Nanomedicine

Scientists change properties of zeolites to improve hemodialysis July 29th, 2016

Pixel-array quantum cascade detector paves the way for portable thermal imaging devices: Research team from TU-Wien Center for Micro- and Nanostructures have developed a new 'cooler' sensing instrument thereby increasing energy-efficiency and enhancing mobility for diagnostic tes July 28th, 2016

Starpharma initiates new DEP™ drug delivery program with AstraZeneca July 27th, 2016

Scientists test nanoparticle drug delivery in dogs with osteosarcoma July 26th, 2016

Announcements

Scientists find a way of acquiring graphene-like films from salts to boost nanoelectronics: Physicists use supercomputers to find a way of making 'imitation graphene' from salt July 30th, 2016

Vortex laser offers hope for Moore's Law: The optics advancement may solve an approaching data bottleneck by helping to boost computing power and information transfer rates tenfold July 30th, 2016

New method for making green LEDs enhances their efficiency and brightness July 30th, 2016

A new type of quantum bits July 29th, 2016

Events/Classes

Nanometrics Announces Upcoming Investor Events July 20th, 2016

n-tech Research Announces August 3, 2016 Date for Smart Coatings Webinar July 18th, 2016

Instrumented Indentation Expert Addresses Trends with Industry Leaders: Leading nanoindentation expert hosts webinar discussing theory and practice of instrumented indentation July 14th, 2016

SUNY Poly Celebrates Its 10th Year Exhibiting at SEMICON West with Cutting Edge Developments in Integrated Photonics and Power Electronics July 8th, 2016

Research partnerships

Vortex laser offers hope for Moore's Law: The optics advancement may solve an approaching data bottleneck by helping to boost computing power and information transfer rates tenfold July 30th, 2016

Lonely atoms, happily reunited July 29th, 2016

New lithium-oxygen battery greatly improves energy efficiency, longevity: New chemistry could overcome key drawbacks of lithium-air batteries July 26th, 2016

Ultrasensitive sensor using N-doped graphene July 26th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic